Pfizer says FDA okays arthritis drug
Pfizer says the Food and Drug Administration approved its rheumatoid arthritis pill Xeljanz, seen as potential big seller for the company.
Pfizer Inc. says the FDA approved Xeljanz as a treatment for moderate to severe rheumatoid arthritis in patients who can't take methotrexate or haven't been helped by it. Xeljanz is intended to slow the progression of the disease. The approval comes about two weeks sooner than expected.
Xeljanz, or tofacitinib, is the first rheumatoid arthritis treatment from a new class of pain medications called JAK inhibitors. The drugs interfere with enzymes that contribute to tissue inflammation.
- Associated Press
Stories that may interest you
Effective July 1, 2018, the sales tax changed from 6.35 percent to 2.99 percent.
Mystic Aquarium has announced that it will extend and revamp its program for Connecticut Electronic Benefit Transfer cardholders by now offering free admission to cardholders and up to three of their guests through Dec. 31.
More than 40 casino shops and dining locations participating in year-round program
Mystic Aquarium will a day of hands on activities on Saturday from 10 a.m. to 2 p.m. in recognition of Long Island Sound Day and to support the health of the estuary.